In 2023, the Chinese Center for Drug Evaluation of the National Medical Products Administration (NMPA) approved 1,829 evaluation applications for biopharmaceuticals that were subjected to technical reviews. The approvals included 891 therapeutic Investigational New Drug (IND) applications, 59 prophylactic IND applications, and 147 New Drug Applications (NDA).
An approved IND application is the prerequisite for a drug product to enter its clinical trial phase, and a drug can only enter the market for general use after its NDA application is approved by the regulatory body.
Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
National Medical Products Administration. (February 4, 2024). Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. "Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application." Chart. February 4, 2024. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. (2024). Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. "Number of Approved Evaluation Applications for Biopharmaceuticals Subjected to Technical Reviews in China in 2023, by Type of Application." Statista, Statista Inc., 4 Feb 2024, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration, Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/ (last visited November 10, 2024)
Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application [Graph], National Medical Products Administration, February 4, 2024. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
